CCP
WST icon

Corient Capital Partners’s West Pharmaceutical WST Stock Holding History

Corient Capital Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$429K Hold
1,418
– – 0.03% 372
2022
Q2 		$429K Buy
1,418
+151
+12% +$49.1K 0.03% 383
2022
Q1 		$520K Buy
1,267
+35
+3% +$13.7K 0.03% 382
2021
Q4 		$578K Buy
1,232
+48
+4% +$20.7K 0.04% 341
2021
Q3 		$503K Buy
1,184
+46
+4% +$19.4K 0.04% 356
2021
Q2 		$409K Buy
1,138
+130
+13% +$43K 0.03% 414
2021
Q1 		$284K Buy
1,008
+149
+17% +$42.6K 0.02% 461
2020
Q4 		$243K Buy
859
+117
+16% +$32.8K 0.02% 432
2020
Q3 		$204K Buy
+742
New +$196K 0.02% 448

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Corient Capital Partners's WST Position: Q3 2022 in Review

Corient Capital Partners held its West Pharmaceutical (WST) position steady in Q3 2022 at 1,418 shares worth $429K. The position accounts for 0.03% of the portfolio, ranked #372.

Corient Capital Partners first reported a position in WST in Q3 2020 and has held it in 9 quarters since. The position peaked at $578K in Q4 2021. 638 funds tracked by Wall St. Rank hold WST as of Q3 2022.

  • Corient Capital Partners held 1,418 shares of West Pharmaceutical worth $429K as of Q3 2022.
  • Corient Capital Partners left its West Pharmaceutical share count unchanged in Q3 2022.
  • West Pharmaceutical made up 0.03% of Corient Capital Partners's portfolio in Q3 2022, its #372 holding.
  • Corient Capital Partners first reported a position in West Pharmaceutical in Q3 2020 and has held it in 9 quarters since.
  • Corient Capital Partners's West Pharmaceutical position peaked at $578K in Q4 2021.
  • 638 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.